Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sangamo Therapeutics (SGMO) Minority Interest (2018 - 2021)

Sangamo Therapeutics (SGMO) has 4 years of Minority Interest data on record, last reported at -$938000.0 in Q1 2021.

  • For Q1 2021, Minority Interest fell 856.45% year-over-year to -$938000.0; the TTM value through Mar 2021 reached -$938000.0, down 856.45%, while the annual FY2020 figure was -$868000.0, 569.19% down from the prior year.
  • Minority Interest reached -$938000.0 in Q1 2021 per SGMO's latest filing, down from -$868000.0 in the prior quarter.
  • Across five years, Minority Interest topped out at $739000.0 in Q4 2018 and bottomed at -$938000.0 in Q1 2021.
  • Average Minority Interest over 4 years is $0.0, with a median of $154500.0 recorded in 2019.
  • Peak YoY movement for Minority Interest: crashed 74.97% in 2019, then tumbled 856.45% in 2021.
  • A 4-year view of Minority Interest shows it stood at $739000.0 in 2018, then plummeted by 74.97% to $185000.0 in 2019, then tumbled by 569.19% to -$868000.0 in 2020, then fell by 8.06% to -$938000.0 in 2021.
  • Per Business Quant database, its latest 3 readings for Minority Interest were -$938000.0 in Q1 2021, -$868000.0 in Q4 2020, and -$530000.0 in Q3 2020.